2026 FAST Global Science Summit
The 2026 FAST Global Science Summit brought together researchers, clinicians, drug developers and families in Orlando, Florida, as part of the 5–7 November summit weekend. Families heard directly from the teams developing potential treatments for Angelman syndrome, with updates on early research, clinical trials and what happens after a trial ends.
Among the clinical trial presentations were updates from Oak Hill Bio on its Phase 3 BEACON study and from Ionis Pharmaceuticals on its Angelman syndrome development programme. Other sessions explored how a person’s genetic subtype can shape the treatment approaches being studied, what researchers are learning from natural history studies, and how potential medicines are assessed for approval.
Families helped shape the discussion, sharing what meaningful changes would look like in everyday life and putting their questions directly to researchers and drug developers.
FAST UK trustees Sarah Washbrook and Louise Prince attended the summit weekend. We were also pleased to see the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) take part in a panel at the scientific meeting alongside the summit, bringing a UK perspective to the international discussion on how potential treatments are evaluated.
Watch the presentations and catch up on the discussions from the 2026 FAST Science Summit to gain a deeper understanding of the research underway, the progress being made and the ongoing international effort to develop meaningful treatments for Angelman syndrome.